

LIPOSORBER® U.S. Treatment Sites

Alabama

Alabama Medical Group (Mobile)

Arizona

Envita Medical Center (Scottsdale)

Mayo Clinic (Phoenix)

Phoenix Children's (Phoenix)

California

Amitabha Medical (Santa Rosa)

Benioff Children's Hospital (Oakland)

Cedars Sinai Medical Center (Los Angeles)

Kaiser Permanente (Los Angeles)

Keck Hospital of USC (Los Angeles)

Loma Linda Medical Center (Loma Linda)

Transfusion Medicine Associates (TMA) (Burlingame)

UC Davis (Sacramento)

UCSD Medical Center (San Diego)

UCSF Cardiovascular Care & Prevention Center (San Francisco)

Colorado

University of Colorado Hospital (Aurora)

Connecticut

Hartford Hospital (Hartford)

Delaware

Alfred I. Dupont Hospital (Nemours) (Wilmington)

Florida

Mayo Clinic (Jacksonville)

Memorial Hospital (Hollywood)

North Ridge Heart Associates (Boca Raton)

University of Miami/Jackson Memorial (Miami)

Georgia

Emory University (Atlanta)

Hawaii

Hawaii Heart Associates (Honolulu)

Illinois

Loyola Univ. Medical Center (Maywood)

Lurie Children's Hospital (Chicago)

NorthShore Evanston Hospital (Evanston)

Indiana

Fresenius Indy - St. Vincent's Hospital (Indianapolis)

Kansas

University of Kansas Medical Center (Kansas City)

Maine

Metabolic Leader LLC (Scarborough)

Maryland

Johns Hopkins Hospital (Baltimore)

Massachusetts

Children's Hospital Boston (Boston)

Partners Hospital - Mass. General (Boston)

Michigan

Helen DeVos Children's Hospital (Grand Rapids)

University of Michigan (Ann Arbor)

Minnesota

Mercy Hospital (Fridley)

Mayo Clinic (Rochester)

Missouri

Barnes-Jewish Hospital (St. Louis)

New Hampshire

Dartmouth Hitchcock Medical (Lebanon)

New Jersey

Atlantic Health Morristown Medical Center (Morristown)

New York

New York Presbyterian Hospital (New York)

Northwell Health/ North Shore (Manhasset)

Sorin Medical (New York)

Westchester Medical Center (Valhalla)

North Carolina

University of NC Lipid Prevention Clinic (Chapel Hill)

Ohio

Akron Children's Hospital (Akron)

Cincinnati Children's Hospital (Cincinnati)

Ohio State University Medical Center (Columbus)

University Hospital of Cleveland (Case Western) (Cleveland)

Oklahoma

Oklahoma Heart Hospital (Oklahoma City)

Oregon

Oregon Health and Science University (Portland)

Pennsylvania

ITxM/Children's Hospital of Pittsburgh (Pittsburgh)

Geisinger Medical Center (Danville)

Lancaster General Health/Penn Medicine (Lancaster)

The Hospital of The University of Pennsylvania (Philadelphia)

South Carolina

Medical University of South Carolina (Charleston)

Tennessee

Vanderbilt University Medical Center (Nashville)

Texas

Baylor Scott & White (Dallas)

Houston Methodist Hospital (Houston)

Parkland Memorial Hospital (Dallas)

Texas Children's Hospital (Houston)

University of Texas Southwestern Medical Center (UTSW) (Dallas)

Utah

bVital Health & Wellness (Park City)

University of Utah Hospital (Salt Lake City)

Utah Lipoprotein Apheresis LLC (Murray)

Virginia

Virginia Commonwealth University Health System (Richmond)

Virginia Nephrology Group (Fairfax)

Washington

Harborview Medical Center (Seattle)

Seattle Children's (Seattle)

Wisconsin

Versiti Blood Center of Wisconsin (Milwaukee)

Wyoming

Campbell County Health (Gillette)

LIPOSORBER®

Provides Hope When Drug Therapy Fails™

FH/Lp(a) Patient Identifier

Referral Guide



Find a Treatment Center:



New facilities are added regularly. Scan the QR code to see the latest.

kaneka

liposorber.com

LIPOSORBER® Indications For Use: FH/Lp(a)

The LIPOSORBER® LA-15 System is indicated for use in performing low density lipoprotein cholesterol (LDL-C) apheresis to acutely remove LDL-C from the plasma of the following high risk patient populations for whom diet has been ineffective and maximum drug therapy has been either ineffective or not tolerated:

- **Group A.** Clinically diagnosed Familial Hypercholesterolemic Homozygotes with LDL-C > 500 mg/dL;
- **Group B.** Clinically diagnosed Familial Hypercholesterolemic Heterozygotes with LDL-C ≥ 300 mg/dL;
- **Group C.** Clinically diagnosed Familial Hypercholesterolemic Heterozygotes with LDL-C ≥ 70 mg/dL and either documented coronary artery disease or documented peripheral artery disease; and
- **Group D.** Clinically diagnosed Familial Hypercholesterolemic Heterozygotes with lipoprotein(a) [Lp(a)] ≥ 60 mg/dL (or 130 nmol/L) and either documented coronary artery disease or documented peripheral artery disease.*

Insurance Guidelines/Supporting Documentation

If clinical indications listed above are met, all diagnosis codes should be chosen by the referring/treating physicians along with:

- **Baseline LDL-C levels** obtained after the patient has had a trial of diet and maximum tolerated combination drug therapy to reduce LDL-C according to the current professional guidelines on the management of blood cholesterol.
- **Documented coronary artery disease (CAD)** - includes CAD diagnosed by invasive or computed tomography (CT) coronary angiography, or by electron beam (ultrafast) CT (EBCT), or documented by a history of myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG) surgery.
- **Documented peripheral artery disease (PAD)** - includes PAD diagnosed by symptoms and/or physician exam, ankle-brachial index (ABI), ultrasound exam, pulse volume recording (PVR), or peripheral vascular angiography, or documented by a history of peripheral vascular intervention, peripheral vascular bypass surgery, or minor or major amputation.
- **Baseline lipid levels** are to be determined after stabilization on diet and drug therapy by making two measurements during a 2- to 4- week period. (Note: The two values should be within 10% of each other, indicating a stable condition).

Referring your Patient for Treatment

- Explain immediate and long-term treatment benefits, such as MACE reduction.
- Explain potential risks (i.e., hypotension, nausea/vomiting, flushing/blotching, etc.) and contraindication (the use of ACE inhibitors).
- Assure you have all required FDA documentation.
- Share patient education - brochures, patient assistance websites, treatment benefits, studies, etc.
- Send referral notes to treating provider/hospital.
- Support patient scheduling appointment with treatment center for a walk-through.
- Schedule follow-up visits to assure treatment outcome.

Referring Algorithm

Clinically diagnosed FH patient for whom diet & maximum drug therapy has been either ineffective or not tolerated.

Lp(a) ≥ 60

LDL-C ≥ 70

LDL-C ≥ 300

Documented CAD/PAD

Patient meets criteria

Patient meets criteria

Refer patient to LIPOSORBER treatment center

LIPOSORBER Safety Information

For LIPOSORBER Indications for Use and safety information (contraindications, adverse events, etc.) please visit: liposorber.com/liposorber-safety-info